Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

ALTseqTM, a rapid ( 48 hours) whole genome sequencing clinical test for Acute Myeloid Leukemia (AML)

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJonathan J. KeatsYCYeneka CampanaCHC.A. HOLDEN

Discussion

Loading...

Member takes

Overview

Clinical test develops fast genomic profiling for AML, indicating timely treatment decisions with actionable insights.

Key Points

  • The research aims to develop a rapid whole genome sequencing assay for better AML treatment decisions.
  • Developed ALTseqTM to deliver genomic results in under 48 hours.
  • Utilized whole blood or bone marrow specimens for sequencing.
  • Employed bioinformatic pipelines for accelerated variant reporting.
  • Achieved average turnaround time of 35.2 hours for genomic reporting.
  • Reported high sensitivity for various genomic aberrations, exceeding 95%.
  • Positive predictive value for variant types is ≥99.5%.

Cite This Study

Keats et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2bchttps://doi.org/10.1182/blood-2025-7036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid diagnosis of acute leukemia with integrated epigenetic and genetic profiling2025 · 2 citations
  2. 2Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients2026
  3. 3Comprehensive and rapid detection of genomic alterations in pediatric leukemias using whole-genome sequencing with adaptive sampling2025 · 1 citations
  4. 4Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice2026
  5. 5Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML2025